Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
Bryan Mehlhaff, MD
Advertisement
Articles by Bryan Mehlhaff, MD
Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).
Advertisement
Latest Updated Articles
Dr. Bryan Mehlhaff on Advances in mCRPCPublished: November 12th 2016 | Updated:
- Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer
Published: November 29th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5